| Dr Janice R Chang, MD | |
|
12 Professional Park Dr, Webster, TX 77598-4127 | |
| (281) 332-8571 | |
| (281) 332-8307 |
| Full Name | Dr Janice R Chang |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 33 Years |
| Location | 12 Professional Park Dr, Webster, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659373579 | NPI | - | NPPES |
| CK2746 | Other | MEDICARE RR | |
| 81341X | Other | TX | BCBS OF TEXAS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | J9477 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oliver Street 5.01(a) Inc | 0042464125 | 141 |
News Archive
OSTAR Healthcare Technology, a Washington State-based Telehealth Solutions company, announced the global launch of its G4 Device Gateway. This revolutionary HIPAA compliant Vendor Neutral Gateway (VNG) provides seamless remote device integration and monitoring for devices such as multi-vendor Glucometers, Vital Signs, Blood Pressure and Weight Scales.
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora")., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer-related products, today announced that data from several clinical trials of nimotuzumab are scheduled be reported at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
News outlets covered a variety of Medicare and Medicaid news, including prospects for Marilyn Tavenner to be confirmed as head of CMS.
› Verified 8 days ago
| Entity Name | Oliver Street 5.01(a) Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457695413 PECOS PAC ID: 0042464125 Enrollment ID: O20130128000189 |
News Archive
OSTAR Healthcare Technology, a Washington State-based Telehealth Solutions company, announced the global launch of its G4 Device Gateway. This revolutionary HIPAA compliant Vendor Neutral Gateway (VNG) provides seamless remote device integration and monitoring for devices such as multi-vendor Glucometers, Vital Signs, Blood Pressure and Weight Scales.
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora")., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer-related products, today announced that data from several clinical trials of nimotuzumab are scheduled be reported at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
News outlets covered a variety of Medicare and Medicaid news, including prospects for Marilyn Tavenner to be confirmed as head of CMS.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Janice R Chang, MD 12 Professional Park Dr, Webster, TX 77598-4127 Ph: (281) 332-8571 | Dr Janice R Chang, MD 12 Professional Park Dr, Webster, TX 77598-4127 Ph: (281) 332-8571 |
News Archive
OSTAR Healthcare Technology, a Washington State-based Telehealth Solutions company, announced the global launch of its G4 Device Gateway. This revolutionary HIPAA compliant Vendor Neutral Gateway (VNG) provides seamless remote device integration and monitoring for devices such as multi-vendor Glucometers, Vital Signs, Blood Pressure and Weight Scales.
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora")., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer-related products, today announced that data from several clinical trials of nimotuzumab are scheduled be reported at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
News outlets covered a variety of Medicare and Medicaid news, including prospects for Marilyn Tavenner to be confirmed as head of CMS.
› Verified 8 days ago
Dr. Karan Kaur Sra, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 202 N Texas Ave Ste 300, Webster, TX 77598 Phone: 346-406-1846 Fax: 346-406-1786 | |
Rashid Rashid, M.D., PH.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 600 N Kobayashi Ste 211, Webster, TX 77598 Phone: 281-941-5556 Fax: 281-557-8335 | |
Dr. Harrison Phu Nguyen, MD, MBA, MPH Dermatology Medicare: Medicare Enrolled Practice Location: 451 N Texas Ave, Webster, TX 77598 Phone: 281-333-3376 Fax: 281-335-4605 | |
Stephen Keith Tyring, MD PHD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 451 N Texas Ave, Webster, TX 77598 Phone: 281-333-2288 Fax: 281-335-4605 | |
Terry E. Williams, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 12 Professional Park Dr, Webster, TX 77598 Phone: 281-332-8571 Fax: 281-332-8307 | |
Dr. Alexander Marzuka, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 750 N Texas Ave Ste 100, Webster, TX 77598 Phone: 346-406-1846 Fax: 346-406-1786 |